Email updates

Keep up to date with the latest news and content from Experimental Hematology and Oncology and BioMed Central.

Open Access Highly Accessed Review

Roles of Polo-like kinase 3 in suppressing tumor angiogenesis

Dazhong Xu1, Qi Wang2, Yongping Jiang3, Yanxi Zhang3, Eleazar Vega-SaenzdeMiera4, Iman Osman4 and Wei Dai13*

Author Affiliations

1 Department of Environmental Medicine, New York University Langone Medical Center, 57 Old Forge Road, Tuxedo, NY 10987, USA

2 Memorial Sloan-Kettering Cancer Center, New York 10023, USA

3 Biopharmaceutical Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China

4 Department of Dermatology, New York University Langone Medical Center, 522 First Avenue, New York, NY 10016, USA

For all author emails, please log on.

Experimental Hematology & Oncology 2012, 1:5  doi:10.1186/2162-3619-1-5

Published: 18 April 2012

Abstract

Angiogenesis is essential for promoting growth and metastasis of solid tumors by ensuring blood supply to the tumor mass. Targeting angiogenesis is therefore an attractive approach to therapeutic intervention of cancer. Tumor angiogenesis is a process that is controlled by a complex network of molecular components including sensors, signaling transducers, and effectors, leading to cellular responses under hypoxic conditions. Positioned at the center of this network are the hypoxia-inducible factors (HIFs). HIF-1 is a major transcription factor that consists of two subunits, HIF-1α and HIF-1β. It mediates transcription of a spectrum of gene targets whose products are essential for mounting hypoxic responses. HIF-1α protein level is very low in the normoxic condition but is rapidly elevated under hypoxia. This dramatic change in the cellular HIF-1α level is primarily regulated through the proteosome-mediated degradation process. In the past few years, scientific progress has clearly demonstrated that HIF-1α phosphorylation is mediated by several families of protein kinases including GSK3β and ERKs both of which play crucial roles in the regulation of HIF-1α stability. Recent research progress has identified that Polo-like kinase 3 (Plk3) phosphorylates HIF-1α at two previously unidentified serine residues and that the Plk3-mediated phosphorylation of these residues results in destabilization of HIF-1α. Plk3 has also recently been found to phosphorylate and stabilize PTEN phosphatase, a known regulator of HIF-1α and tumor angiogenesis. Given the success of targeting protein kinases and tumor angiogenesis in anti-cancer therapies, Plk3 could be a potential molecular target for the development of novel and effective therapeutic agents for cancer treatment.

Keywords:
Plk3; Tumor angiogenesis; Tumor suppression; HIF-1α; PTEN